A groundbreaking clinical trial led by Dr. Zev Wainberg at UCLA Health has revealed promising results for a new drug, daraxonrasib, in treating advanced pancreatic cancer. This development is particularly significant given the typically grim prognosis associated with this disease.

Promising Results in Clinical Trials

In a phase 3 trial involving 500 patients, daraxonrasib demonstrated the ability to double the survival time of patients with advanced pancreatic cancer, extending it to an average of 13.2 months compared to 6.7 months for those receiving chemotherapy. These findings were presented at the American Society of Clinical Oncology’s annual meeting and published in the New England Journal of Medicine.

The drug targets a mutation in the KRAS gene, which is prevalent in over 90% of pancreatic cancers. This mutation causes cancer cells to grow uncontrollably. Daraxonrasib works by pairing with a protein inside cells, effectively acting as a ‘molecular glue’ to inhibit the mutated protein’s effect.

Expanding Horizons

Excitement around daraxonrasib is not limited to pancreatic cancer. The drug’s mechanism of targeting the KRAS mutation holds potential for treating other cancers, including lung, colorectal, and ovarian cancers. Dr. Brian Wolpin from Dana-Farber Cancer Institute expressed optimism about the drug’s broader applications.

The FDA has fast-tracked daraxonrasib for approval, and Revolution Medicines, the company behind the drug, is preparing for its wider availability. The company is also developing additional drugs targeting similar mutations, aiming to provide a robust arsenal against cancer.

Patient Experiences and Future Outlook

Patients like Debby Orcutt, who participated in the trial, have reported significant improvements. Orcutt’s liver spots vanished, and her pancreatic tumor shrank by 80%. Despite some side effects like rashes and sores, the benefits have been life-changing for many.

While not a cure, daraxonrasib represents a significant step forward in cancer treatment, offering hope and extended time for patients and their families. As research continues, the medical community remains hopeful about reducing reliance on chemotherapy and improving quality of life for cancer patients.

Original reporting: Dallas TX News (HLL/CB) — read the source article.